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Different conformers of the immunosuppressant cyclosporin A have been observed instructural studies of the isolated molecule and of its complex 
with cyclophilin or with an Fab fragment. The factors that control this conformational change are not well understood. Variations in the amount 
of complex formed with cyclophilin or with the antibody were measured as a function of time after adding cyclosporin to the proteins, using the 
Pharmacia BIAcore biosensor instrument. Up to 1 hour was needed to reach maximum complex formation in solution, which is likely to reflect 
the time needed for a conformational transition ofcyclosporin. The equilibrium affinity constant of both proteins for cyclosporin has been measured. 
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1. INTRODUCTION 
Cyclosporin A (CS) is a cyclic peptide composed of 
11 residues which is used as an immunosuppressive drug 
under the trade name Sandimmune. Recently the struc- 
tures of two complexes of CS with a protein have been 
published. The complex between CS and the Fab frag- 
ment of a monoclonal antibody has been solved by 
crystallographic analysis to 2.65 /k resolution [1]. The 
structure of CS complexed to cyclophilin (CYP), its 
binding protein in vivo, has also been obtained both by 
X-ray crystallography [2] and nuclear magnetic reso- 
nance [3,4]. The conformation of CS in the two com- 
plexes is similar and totally different from its conforma- 
tion in an isolated form as determined by X-ray and 
NMR analyses in organic solvents [5,6]. A striking dif- 
ference between isomers is that the MeLeu9-MeLeu 1° 
peptide bond is cis in isolated CS and trans in com- 
plexed CS. Moreover, isolated CS contains three intra- 
molecular hydrogen bonds, while in complexed CS, car- 
bonyles and nitrogens are available for hydrogen bond- 
ing to the proteins or to water. 
CS can thus adopt at least two conformations, but the 
factors that control its conformational change are not 
well understood. The observation that CS complexed to 
the Fab has all trans amide bonds suggested that the 
proteins bind the trans conformation that could pre- 
exist in aqueous solution [1]. This hypothesis was 
strenghtened by results of Kofron and coworkers [7] 
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who have shown the presence of different conformers 
in solution, the ratio of which depends on the initial 
solvent used for dissolution. These authors also showed 
a time-dependent i hibition of the rotamase activity of 
CYP, which was interpreted as a slow interconversion 
between two conformers, the trans conformer being 
bound by CYR and the cis conformer not. 
Changes in the ability of CS to bind to the Fab or to 
CYP as a function of time have been directly measured, 
using a new biosensor technology (BIAcore, Pharma- 
cia). These experiments clearly demonstrate hat up to 
one hour is needed to reach maximum complex forma- 
tion in solution, implying that reproducible binding 
measurements with CS require carefully controlled ex- 
perimental conditions. We have also compared the af- 
finity of CYP and of the Fab fragment of an anti CS 
monoclonal antibody for CS. The results thus obtained 
with the biosensor technology are compatible with the 
hypothesis of a time consuming 'hydrophobic collapse' 
of CS in aqueous media to generate the bioactive drug 
shape prior to binding to CYP [8]. 
2. MATERIALS AND METHODS 
2. l. Fab preparation and purification 
Antibody preparation and papain digestion were conducted as de- 
scribed previously [9], except hat gel filtration was performed on a 
Hiload 26/60 Superdex 200 column (Pharmacia) instead ofa Sephacryl 
S-200 superfine (Pharmacia) column. Concentration of the purified 
Fab was determined by the Bradford [10] colorimetric micromethod 
assay, using bovine immunoglobulins (BioRad, ref. 500-0005) as 
standard [11]. 
2.2. Equipment and reagents 
The BIAcore system, sensor chips CM5, surfactant P20, N-hydrox- 
Published by Elsevier Science Publishers R ~ 153 
Volume 326, number  1,2,3 FEBS LETTERS July 1993 
1520( 
1486C 
14520 
14180 
13840 
13500 
50 
/ A 
150 250 350 450 
T ime [s] 
12OO 
1000 B 
8O0 
R U 600 
40O - 
200 - 
0 -  
,oo  ~oo 3oo 
conc .  nM 
Fig. 1. (A) Sensorgram corresponding to the injection of a 15 nM Fab 
solution on a BSA/CS surface. The difference in response between 
report points 2 and 1 corresponds to the RU value reported in the 
calibration curve. (B) Example of calibration curves constructed with 
known concentrations of Fab (black squares) or CYP (open circles). 
These curves are used for the evaluation of free protein in protein CS 
mixtures. 
through washing the surface with 15 pl of 10% acetonitrile in 0.1 M 
NaOH. In these conditions 3000-5000 resonance units (RUs) of BSA- 
CS conjugate were immobilized. 
2.4. Monitoring of changes inprotein CS interaction with time 
CS was dissolved from lyophilized powder at a concentration f 1 
mg/ml in either dimethyl sulfoxide (DMSO), or trifluoroethanol 
(TFE), or TFE containing 0.47 M of lithium chloride (LiCI). 120 to 
250 nM solutions of CS in HBS buffer were prepared from the 1 mg/ml 
stock solution. The amount of free protein (antibody V45-271-11 or 
CYP) present in a CS-protein mixture was followed over time by 
injecting repeatedly the CS protein mixture on a BSA/CS immobilized 
surface. In order to shorten the time between two successive injections, 
only 20 ,ul were injected at a flow rate of 10/A/min, followed by 4~1 
of the regeneration solution, which was 0.1 M HCI in the case of CYP 
and 10% acetonitrile in 0.1 M NaOH in the case of the antibody. The 
protein response was read 10 s before regeneration. Readings were 
thus obtained every 7 min, starting 5 min after adding CS to the 
protein. The antibody and CYP concentrations were 50 and 100 nM, 
respectively. Concentrations of CS were chosen so that approximately 
50% of the protein remained free for binding to BSA/CS. These con- 
centrations were 75 and 250 nM for the antibody and CYP respec- 
tively. 
2.5. Equilibrium affinity measurements 
Constant CS concentrations were mixed with increasing amounts 
of protein and incubated for 1 h. The protein-CS mixture was injected 
on a BSA/CS surface. The free protein bound to the immobilized CS. 
The response l vel in RUs was expressed as free protein concentration~ 
using a calibration curve established with known protein concentra- 
tions on the same surface. Data were analysed using Scatchard plots. 
The procedure used for calibration of the surface with known pro- 
tein concentrations and titration of free protein in protein-CS mix- 
tures was as described above. A sensorgram corresponding to the 
injection of a 10 nM Fab solution is shown in Fig. 1A. The Fab 
fragment was used instead of the whole antibody to avoid problems 
linked with antibody bivalency. Typical calibration curves, obtained 
by injecting the Fab at concentrations comprised between 2 and 40 
nM, or CYP at concentrations ranging from 5 to 250 nM, are shown 
in Fig. lB. 
3. RESULTS AND DISCUSSION 
ysuccinimide (NHS), N-ethyl-N'-(3-dimethyl-aminopropyl)carbodi- 
imide hydrochloride (EDC) and 1M ethanolamine-hydrochloride pH 
8.5 were obtained from Pharmacia Biosensor AB, Uppsala Sweden. 
CS, CYP A, monoclonal antibody V45-271-11 and a D-LystCS/ 
BSA conjugate [12] (BSA/CS) were kindly provided by Drs. H.-P. 
Kocher, V.F.J. Quesniaux, M. Schreier and M. Zurini (Sandoz, 
Basel). The antibody to CS used in the present study is antibody 
V45-271-11 [12]. This antibody differs from antibody R45-45-11 used 
for crystallographic analysis of an Fab-CS complex [1] by a single 
amino acid change of Phe to Tyr at position 58 (Kabat numbering, 
[13]) located in the H2 loop [14]. Crystallographic analysis hows that 
this amino acid does not contact CS [15]. 
2.3. Immobilization f BSA CS conjugate 
The standard immobilization technique was used to couple the 
BSA/CS conjugate through primary amino groups to the carboxylated 
dextran matrix of a CM5 sensor chip [16,17]. The flow rate was 5 
,ul/min, using as running buffer HBS, pH 7.4 (10 mM HEPES, 150 mM 
NaC1, 3.4 mM EDTA, 0.05% surfactant P20). In order to immobilize 
large amounts of the conjugate, activation of the carboxylated dextran 
matrix of CM5 sensor chips by the EDC/NHS mixture was increased 
to 8 min, and BSA/CS was injected in three successive steps of 8, 3 and 
3 rain at a concentration of 7.5/.tg/ml in 10 mM formate buffer, pH 
3.0. Remaining NHS-ester groups were blocked by injection of 35/.tl 
of ethanolamine. Non-covalently attached protein was removed 
3.1. Monitoring changes in protein-CS interaction with 
time 
CS so lu t ions  in HEPES buf fer  were prepared  f rom 1 
mg/ml  so lu t ions  in DMSO,  TFE  or  TFE/L iC1.  The  level 
o f  free prote in  (CYP  or ant ibody)  was measured  every  
7 ra in  fo l lowing  add i t ion  o f  CS in HEPES buf fer  to the 
prote ins ,  by  repeated  in ject ion  o f  the  mixture  on  a BSA/  
CS immobi l i zed  sensor  surface.  Fig. 2 shows resul ts  
obta ined  w i th  the ant ibody  at  room temperature .  The  
level o f  free ant ibody  decreases  in the first ha l f -hour  
fo l low ing  the add i t ion  o f  CS to the ant ibody ,  ind icat ing  
that  the amount  o f  complex  fo rmed in so lu t ion  in- 
creases w i th  t ime. The  t ime needed to reach  a stable  
level o f  CS-ant ibody  complex  is l ikely to ref lect a con-  
fo rmat iona l  t rans i t ion  o f  CS. Ko f ron  et al. [7] observed  
d i f ferent  behav iours  for  CS in i t ia l ly  d isso lved in TFE  
and  TFE/L iC1.  In our  case, read ings  obta ined  wi th  CS 
d isso lved in TFE /L iC I  (Fig. 2B) were on ly  s l ight ly more  
stab le  than  those  obta ined  wi th  CS d isso lved in TFE  
(Fig. 2A).  
A cont ro l  cor respond ing  to ant ibody  in the absence  
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Fig. 2. Changes in the antibody-CS interaction with time, when the 
initial 1 mg/ml CS solutions were prepared either in TFE (A), TFE/ 
LiCI (B) or DMSO (C), 2 h (black triangles) or several days before the 
experiment (open circles). CS solution in HEPES buffer was prepared 
just before the experiment. Controls correspond to antibody in the 
absence of CS (black squares) and antibody first incubated during 2 
h with CS (open squares). 
of solution CS is represented by black squares (Fig. 2). 
The control shows a slight decrease in binding at each 
injection cycle. This small decrease (less than 1% per 
cycle) corresponds to BSA/CS leaking from the surface 
at each washing step. A drastic surface regeneration 
with 10% acetonitrile in 0.1 M NaOH was necessary to 
dissociate the bound antibody from the BSA/CS sur- 
face. 
Open squares represent an additional control where 
CS and the antibody were incubated 2 h before starting 
to monitor the free antibody level. Readings were then 
constant over time, indicating that differences in bind- 
ing observed immediately after mixing the proteins were 
real, and not an experimental rtifact. 
Similar results were obtained with CYP and are 
shown in Fig. 3 for CS initially dissolved in DMSO. The 
decrease in free protein level was slower at 4°C (Fig. 
3A) than at room temperature (Fig. 3B). Controls cor- 
responding to CYP in the absence of CS (black squares) 
or after 2 h incubation (open squares) are more stable 
than for the antibody because surface regeneration was 
less drastic (0.1 M HC1). 
The CS powder was typically dissolved in apolar sol- 
vents at least 2 h before the experiment, while the CS 
solution in HEPES buffer was prepared just before the 
experiment. Fig. 3 shows that the binding capacity of 
CS was weak immediately after dissolving the powder 
(open triangles), presumably because some time is 
needed for complete dissolution. Superimposable re- 
sults were obtained whether the CS solution in HEPES 
buffer was prepared immediately or several hours be- 
fore the experiment (data not shown), indicating that 
the conformational change occurs in the presence of the 
proteins and not spontaneously when the drug leaves 
the apolar solution and enters the aqueous buffer. The 
most likely explanation is that the proteins shift the 
equilibrium between different conformers by preferen- 
tial binding to one of them. 
However, when the drug was initially dissolved in 
DMSO, the decrease in free protein level was slightly 
larger when the HEPES solution of CS had just been 
prepared, compared to a solution prepared several 
hours beforehand (results not shown). 
3.2. Theoretical considerations for  equilibrium affinity 
measuremen ts 
The range of Kd values that can be evaluated is limited 
by the measurable range of free ligand concentrations, 
as indicated by the upper and lower limits of the calibra- 
tion curve (Fig. 1B). Maximum precision is reached in 
the steepest part of the curve. Fig. 1B shows that the 
lowest free protein concentrations that can be measured 
are roughly 2 nM for the Fab and 5 nM for CYR This 
difference is due to the fact that the response in RUs of 
bound ligand is directly proportional to the ligand mo- 
lecular weight (Fab: MW 50,000; CYP: MW 17900). 
The protein to CS ratios that must be used in order 
to have free protein concentrations lying in this measur- 
able range can be calculated from the equation of the 
law of mass action. When using the symbols of Hardie 
and Van Regenmortel [18], the equation reads: 
Ka = ny 
(As - ny) (Bn - ny) 
where A = total CS concentration; s = CS valence; As 
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Fig. 3. Changes in the CYPCS interaction with time, measured at4 ° C 
(A) or at room temperature (B). CS solution (1 mg/ml) in DMSO was 
prepared 2 h (black triangles) or just before the experiment (open 
triangles). Controls correspond to CYP in the absence of CS (black 
squares) and CYP first incubated uring 2 h with CS (open squares). 
= total CS sites; B = total protein concentration; n = 
ligand valence; Bn = total protein sites; y = bound pro- 
tein concentration; y = bound sites. 
To construct Scatchard plots, this equation is rear- 
ranged in the form: 
f = Ka (s -  nJ) 
d 
where f = y/A = ratio of  bound protein to total CS; d 
= free protein concentration. 
Whenf/d is plotted versus f, a straight line is obtained, 
the slope of which is K~ s. The extrapolation on the 
x-axis gives s/n. 
In Fig. 4, the d value expected fo r f rang ing  from 0.1 
to 0.9 has been calculated for Ka values of  10 7, 10 8 and 
109 M -~. The range of d values (nM) that can be most 
accurately measured (steepest part of  the calibration 
curve) is shaded. From Fig. 4, it is clear that Ka values 
around 108 M 1 will lead to easily measurable free pro- 
tein concentrations (d). Ka values that are larger than 
10 9 M -l cannot be determined because the free protein 
concentrations are too low to be measured. Ka values 
that are much smaller than 10 7 M -] cannot be deter- 
mined because free protein concentrations are too large. 
3.3. Experimental data for equilibrium affinity measure- 
ments 
Since a stable equilibrium is reached only after one 
hour, equilibrium affinity measurements were per- 
formed after one hour incubation time. Typical 
Scatchard plots for the interaction between CS and 
CYP or the Fab are shown in Figs. 5A and 5B, respec- 
tively. The affinity of  CYP for CS is in the 100 nM 
range, while that of  the Fab is in the nM range. As 
indicated in Fig. 4, f values below 0.7 could not be 
obtained for the CS-Fab  interaction because the free 
Fab concentration was too low to be measured. The 
x-axis extrapolation (s/n) should be equal to 1 since both 
CS and the proteins are expected to be monovalent. For 
the Fab CS interaction, s/n was close to 0.82, which 
could mean that either the antigen valency is larger than 
one, or the antibody valency is smaller than one. How- 
ever, in our case, it seems likely that this value results 
from an error in the evaluation of  active Fab and/or CS 
concentrations. 
Experiments were performed at least twice. The equi- 
librium affinity constant for the Fab-CS interaction has 
been measured for CS initially dissolved in TFE,  
DMSO and TFE/LiC1. The calculated values were 
3.7 + 0.6, 3.6 + 1.0 and 3.7 + 0.2 x 10 9 M -I ,  respec- 
140 7 
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4O 
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f 
Fig. 4. Theoretical curves howing free antibody concentrations (d) 
expected for affinity values of 10 7, lO 8 and  10 9 M ~. 
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complete cycle including surface regeneration lasts only 
7 min. We were thus able to follow slow conformational 
changes of CS by directly following its binding to the 
antibody or to CYP. 
Knowledge of the experimental conditions required 
to reach stable complex formation is crucial for repro- 
ducible monitoring of the drug and for the analysis of 
structure activity correlates. Factors such as tempera- 
ture, procedure used to dissolve CS, and time of incuba- 
tion of CS with proteins must be controlled. The 
method presented here for analysing conformational 
states of CS should also be useful for the rapid screening 
of derivatives showing the desired CYP binding proper- 
ties. 
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